Y-90 Dosing and Ablation Modalities for Hepatocellular Carcinoma
This course covers Y-90 dosimetry, curative intent therapies for HCC, and practical guidance for building a successful interventional oncology practice, offering clinicians the tools to optimize treatment strategies and patient outcomes. The course is supported by an educational grant from AstraZeneca, with additional support from Boston Scientific.